Gain Therapeutics (NASDAQ:GANX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock.

Other equities analysts have also recently issued research reports about the stock. Chardan Capital reaffirmed a “buy” rating and set a $6.00 price target on shares of Gain Therapeutics in a research report on Friday, March 28th. Scotiabank initiated coverage on Gain Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 price target for the company. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Gain Therapeutics presently has an average rating of “Buy” and a consensus price target of $8.20.

Gain Therapeutics Price Performance

Gain Therapeutics stock opened at $1.69 on Thursday. Gain Therapeutics has a 52-week low of $0.89 and a 52-week high of $3.19. The firm has a fifty day moving average of $1.87 and a 200-day moving average of $2.00. The company has a quick ratio of 2.22, a current ratio of 2.22 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $50.62 million, a P/E ratio of -1.97 and a beta of 0.12.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.16) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.16). As a group, analysts predict that Gain Therapeutics will post -1 EPS for the current year.

Institutional Trading of Gain Therapeutics

A number of large investors have recently added to or reduced their stakes in GANX. Northern Trust Corp lifted its stake in Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after acquiring an additional 39,642 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in Gain Therapeutics by 83.6% in the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after buying an additional 44,750 shares during the last quarter. Marshall Wace LLP acquired a new stake in Gain Therapeutics in the 4th quarter worth $198,000. Bridgeway Capital Management LLC bought a new stake in shares of Gain Therapeutics during the fourth quarter valued at approximately $65,000. Finally, Kovitz Investment Group Partners LLC bought a new stake in Gain Therapeutics in the first quarter valued at about $91,000. 11.97% of the stock is currently owned by institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.